<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39458594</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1999-4923</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Pharmaceutics</Title><ISOAbbreviation>Pharmaceutics</ISOAbbreviation></Journal><ArticleTitle>Multidrug Combinations against SARS-CoV-2 Using GS-441524 or Ivermectin with Molnupiravir and/or Nirmatrelvir in Reconstituted Human Nasal Airway Epithelia.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1262</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmaceutics16101262</ELocationID><Abstract><AbstractText><b>Background.</b> The emergence, global spread, and persistence of SARS-CoV-2 resulted in an unprecedented need for effective antiviral drugs. Throughout the pandemic, various drug development and treatment strategies were adopted, including repurposing of antivirals designed for other viruses along with a multitude of other drugs with varying mechanisms of action (MoAs). Furthermore, multidrug treatment against COVID-19 is an ongoing topic and merits further investigation. <b>Method/Objectives.</b> We assessed the efficacy of multidrug treatment against SARS-CoV-2 in reconstituted human nasal epithelia, using combinations of molnupiravir and nirmatrelvir as a baseline, adding suboptimal concentrations of either GS-441524 or ivermectin, attempting to increase overall antiviral activity while lowering the overall therapeutic dose. <b>Results.</b> Nirmatrelvir combined with molnupiravir, GS-441524, or ivermectin at suboptimal concentrations show increased antiviral activity compared to single treatment. No triple combinations showed improved inhibition of SARS-CoV-2 replication beyond what was observed for double treatments. <b>Conclusions.</b> In general, we observed that the addition of a third compound is not beneficial for antiviral activity, while various double combinations exhibit increased antiviral activity over single treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Siegrist</LastName><ForeName>Denise</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Spiez Laboratory, Federal Office for Civil Protection, 3700 Spiez, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonsdottir</LastName><ForeName>Hulda R</ForeName><Initials>HR</Initials><Identifier Source="ORCID">0000-0001-7509-5970</Identifier><AffiliationInfo><Affiliation>Spiez Laboratory, Federal Office for Civil Protection, 3700 Spiez, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of BioMedical Research, University of Bern, 3008 Bern, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Inselspital University Hospital, 3010 Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouveret</LastName><ForeName>Mendy</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Epithelix Sàrl, Plan-les-Ouates, 1228 Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boda</LastName><ForeName>Bernadett</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Epithelix Sàrl, Plan-les-Ouates, 1228 Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Constant</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Epithelix Sàrl, Plan-les-Ouates, 1228 Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engler</LastName><ForeName>Olivier B</ForeName><Initials>OB</Initials><Identifier Source="ORCID">0000-0002-8404-1496</Identifier><AffiliationInfo><Affiliation>Spiez Laboratory, Federal Office for Civil Protection, 3700 Spiez, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>INV-016776</GrantID><Acronym>GATES</Acronym><Agency>Bill &amp; Melinda Gates Foundation</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceutics</MedlineTA><NlmUniqueID>101534003</NlmUniqueID><ISSNLinking>1999-4923</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">GS-441524</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antivirals</Keyword><Keyword MajorTopicYN="N">ivermectin</Keyword><Keyword MajorTopicYN="N">molnupiravir</Keyword><Keyword MajorTopicYN="N">nirmatrelvir</Keyword><Keyword MajorTopicYN="N">reconstituted human nasal epithelia</Keyword></KeywordList><CoiStatement>Authors Mendy Bouveret, Bernadett Boda and Samuel Constant are employed by the company Epithelix. All authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39458594</ArticleId><ArticleId IdType="pmc">PMC11510096</ArticleId><ArticleId IdType="doi">10.3390/pharmaceutics16101262</ArticleId><ArticleId IdType="pii">pharmaceutics16101262</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gordon D.E., Jang G.M., Bouhaddou M., Xu J., Obernier K., White K.M., O’Meara M.J., Rezelj V.V., Guo J.Z., Swaney D.L., et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459–468. doi: 10.1038/s41586-020-2286-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2286-9</ArticleId><ArticleId IdType="pmc">PMC7431030</ArticleId><ArticleId IdType="pubmed">32353859</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan H., Richard Peto F.R., Karim Q.A., Marissa Alejandria M.D., Henao-Restrepo A.M., García C.H., Kieny M.P., Reza Malekzadeh M.D., Murthy S., Srinath Reddy M.D., et al. Repurposed Antiviral Drugs for Covid-19—Interim WHO Solidarity Trial Results. N. Engl. J. Med. 2021;384:497–511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7727327</ArticleId><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel J.H. Remdesivir for the Treatment of Covid-19—Final Report. N. Engl. J. Med. 2020;383:1813–1826. doi: 10.1056/NEJMoa2007764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Zhang D., Du G., Du R., Zhao J., Jin Y., Fu S., Gao L., Cheng Z., Lu Q., et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–1578. doi: 10.1016/S0140-6736(20)31022-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31022-9</ArticleId><ArticleId IdType="pmc">PMC7190303</ArticleId><ArticleId IdType="pubmed">32423584</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler C.C., Hobbs F.R., Gbinigie O.A., Rahman N.M., Hayward G., Richards D.B., Dorward J., Lowe D.M., Standing J.F., Breuer J., et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): An open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401:281–293. doi: 10.1016/S0140-6736(22)02597-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02597-1</ArticleId><ArticleId IdType="pmc">PMC9779781</ArticleId><ArticleId IdType="pubmed">36566761</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayk Bernal A., Gomes da Silva M.M., Musungaie D.B., Kovalchuk E., Gonzalez A., Delos Reyes V., Martín-Quirós A., Caraco Y., Williams-Diaz A., Brown M.L., et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N. Engl. J. Med. 2022;386:509–520. doi: 10.1056/NEJMoa2116044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai W., Zhang B., Jiang X.M., Su H., Li J., Zhao Y., Xie X., Jin Z., Peng J., Liu F., et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020;368:1331–1335. doi: 10.1126/science.abb4489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb4489</ArticleId><ArticleId IdType="pmc">PMC7179937</ArticleId><ArticleId IdType="pubmed">32321856</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan B.X., Shuai H., Xia A.J., Hou Y., Zeng R., Liu X.L., Lin G.F., Qiao J.X., Li W.P., Wang F.L., et al. An orally available M(pro) inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron. Nat. Microbiol. 2022;7:716–725. doi: 10.1038/s41564-022-01119-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01119-7</ArticleId><ArticleId IdType="pubmed">35477751</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanimoto T., Tada S., Fujita S., Hirakawa T., Matsumura M., Isoyama S., Ueno S., Hamai K., Tsuji N., Hirosawa H., et al. Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study. Respir. Investig. 2022;60:418–424. doi: 10.1016/j.resinv.2022.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resinv.2022.02.004</ArticleId><ArticleId IdType="pmc">PMC8898743</ArticleId><ArticleId IdType="pubmed">35307364</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin R. Baricitinib Is First Approved COVID-19 Immunomodulatory Treatment. JAMA. 2022;327:2281. doi: 10.1001/jama.2022.9846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.9846</ArticleId><ArticleId IdType="pubmed">35727290</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodde C., Timmen F., Hohenstein S., Bollmann A., Bonsignore M., Kuhlen R., Nachtigall I., Tasci S. Impact of Dexamethasone on the Pathogen Profile of Critically Ill COVID-19 Patients. Viruses. 2023;15:1076. doi: 10.3390/v15051076.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15051076</ArticleId><ArticleId IdType="pmc">PMC10220814</ArticleId><ArticleId IdType="pubmed">37243161</ArticleId></ArticleIdList></Reference><Reference><Citation>Arcani R., Cauchois R., Suchon P., Jean R., Jarrot P.A., Gomes De Pinho Q., Dalmas J.B., Jean E., Andre B., Veit V., et al. Factors associated with dexamethasone efficacy in COVID-19. A retrospective investigative cohort study. J. Med. Virol. 2022;94:3169–3175. doi: 10.1002/jmv.27712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27712</ArticleId><ArticleId IdType="pmc">PMC9088322</ArticleId><ArticleId IdType="pubmed">35277862</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolzali M.M.R., Noori M., Shokri P., Rahmani S., Khanzadeh S., Nejadghaderi S.A., Fazlollahi A., Sullman M.J.M., Singh K., Kolahi A., et al. Efficacy of tocilizumab in the treatment of COVID-19: An umbrella review. Rev. Med. Virol. 2022;32:e2388. doi: 10.1002/rmv.2388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2388</ArticleId><ArticleId IdType="pmc">PMC9539231</ArticleId><ArticleId IdType="pubmed">36029180</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliynyk O., Barg W., Slifirczyk A., Oliynyk Y., Gurianov V., Rorat M. Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome. Viruses. 2021;13:1067. doi: 10.3390/v13061067.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13061067</ArticleId><ArticleId IdType="pmc">PMC8229480</ArticleId><ArticleId IdType="pubmed">34205217</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese E., Samuel S.M., Liskova A., Kubatka P., Büsselberg D. Diabetes and coronavirus (SARS-CoV-2): Molecular mechanism of Metformin intervention and the scientific basis of drug repurposing. PLoS Pathog. 2021;17:e1009634. doi: 10.1371/journal.ppat.1009634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009634</ArticleId><ArticleId IdType="pmc">PMC8219155</ArticleId><ArticleId IdType="pubmed">34157054</ArticleId></ArticleIdList></Reference><Reference><Citation>Cory T.J., Emmons R.S., Yarbro J.R., Davis K.L., Pence B.D. Metformin Suppresses Monocyte Immunometabolic Activation by SARS-CoV-2 Spike Protein Subunit 1. Front. Immunol. 2021;12:733921. doi: 10.3389/fimmu.2021.733921.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.733921</ArticleId><ArticleId IdType="pmc">PMC8631967</ArticleId><ArticleId IdType="pubmed">34858397</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaccour C., Casellas A., Blanco-Di Matteo A., Pineda I., Fernandez-Montero A., Ruiz-Castillo P., Richardson M.A., Rodríguez-Mateos M., Jordán-Iborra C., Brew J., et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine. 2021;32:100720. doi: 10.1016/j.eclinm.2020.100720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100720</ArticleId><ArticleId IdType="pmc">PMC7816625</ArticleId><ArticleId IdType="pubmed">33495752</ArticleId></ArticleIdList></Reference><Reference><Citation>López-Medina E., López P., Hurtado I.C., Dávalos D.M., Ramirez O., Martínez E., Díazgranados J.A., Oñate J.M., Chavarriaga H., Herrera S., et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults with Mild COVID-19: A Randomized Clinical Trial. JAMA. 2021;325:1426–1435. doi: 10.1001/jama.2021.3071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.3071</ArticleId><ArticleId IdType="pmc">PMC7934083</ArticleId><ArticleId IdType="pubmed">33662102</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung I.F.-N., Lung K.-C., Tso E.Y.-K., Liu R., Chung T.W.-H., Chu M.-Y., Ng Y.-Y., Lo J., Chan J., Tam A.R., et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An open-label, randomised, phase 2 trial. Lancet. 2020;395:1695–1704. doi: 10.1016/S0140-6736(20)31042-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31042-4</ArticleId><ArticleId IdType="pmc">PMC7211500</ArticleId><ArticleId IdType="pubmed">32401715</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao B., Wang Y., Wen D., Liu W., Wang J., Fan G., Ruan L., Song B., Cai Y., Wei M., et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N. Engl. J. Med. 2020;382:1787–1799. doi: 10.1056/NEJMoa2001282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001282</ArticleId><ArticleId IdType="pmc">PMC7121492</ArticleId><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference><Reference><Citation>Franco E.J., Drusano G.L., Hanrahan K.C., Warfield K.L., Brown A.N. Combination Therapy with UV-4B and Molnupiravir Enhances SARS-CoV-2 Suppression. Viruses. 2023;15:1175. doi: 10.3390/v15051175.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15051175</ArticleId><ArticleId IdType="pmc">PMC10224493</ArticleId><ArticleId IdType="pubmed">37243261</ArticleId></ArticleIdList></Reference><Reference><Citation>Orth H.M., Flasshove C., Berger M., Hattenhauer T., Biederbick K.D., Mispelbaum R., Klein U., Stemler J., Fisahn M., Doleschall A.D., et al. Early combination therapy of COVID-19 in high-risk patients. Infection. 2024;52:877–889. doi: 10.1007/s15010-023-02125-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-023-02125-5</ArticleId><ArticleId IdType="pmc">PMC11142969</ArticleId><ArticleId IdType="pubmed">38017344</ArticleId></ArticleIdList></Reference><Reference><Citation>Günthard H.F., Calvez V., Paredes R., Pillay D., Shafer R.W., Wensing A.M., Jacobsen D.M., Richman D.D. Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel. Clin. Infect. Dis. 2019;68:177–187. doi: 10.1093/cid/ciy463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciy463</ArticleId><ArticleId IdType="pmc">PMC6321850</ArticleId><ArticleId IdType="pubmed">30052811</ArticleId></ArticleIdList></Reference><Reference><Citation>Su T.-H., Liu C.-J. Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives. Gut Liver. 2017;11:590–603. doi: 10.5009/gnl16215.</Citation><ArticleIdList><ArticleId IdType="doi">10.5009/gnl16215</ArticleId><ArticleId IdType="pmc">PMC5593320</ArticleId><ArticleId IdType="pubmed">28494575</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitley R.J., Monto A.S. Resistance of Influenza Virus to Antiviral Medications. Clin. Infect. Dis. 2020;71:1092–1094. doi: 10.1093/cid/ciz911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciz911</ArticleId><ArticleId IdType="pubmed">31538179</ArticleId></ArticleIdList></Reference><Reference><Citation>Rong L., Dahari H., Ribeiro R.M., Perelson A.S. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci. Transl. Med. 2010;2:30ra32. doi: 10.1126/scitranslmed.3000544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3000544</ArticleId><ArticleId IdType="pmc">PMC3033690</ArticleId><ArticleId IdType="pubmed">20445200</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsdottir H.R., Siegrist D., Julien T., Padey B., Bouveret M., Terrier O., Pizzorno A., Huang S., Samby K., Wells T.N., et al. Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro. Biomed. Pharmacother. 2022;150:113058. doi: 10.1016/j.biopha.2022.113058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.113058</ArticleId><ArticleId IdType="pmc">PMC9057985</ArticleId><ArticleId IdType="pubmed">35658229</ArticleId></ArticleIdList></Reference><Reference><Citation>Maas B.M., Strizki J., Miller R.R., Kumar S., Brown M., Johnson M.G., Cheng M., De Anda C., Rizk M.L., Stone J.A. Molnupiravir: Mechanism of action, clinical, and translational science. Clin. Transl. Sci. 2024;17:e13732. doi: 10.1111/cts.13732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.13732</ArticleId><ArticleId IdType="pmc">PMC10851176</ArticleId><ArticleId IdType="pubmed">38593352</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen D.R., Allerton C.M., Anderson A.S., Aschenbrenner L., Avery M., Berritt S., Boras B., Cardin R.D., Carlo A., Coffman K.J., et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374:1586–1593. doi: 10.1126/science.abl4784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abl4784</ArticleId><ArticleId IdType="pubmed">34726479</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P., Wang Y., Lavrijsen M., Lamers M.M., de Vries A.C., Rottier R.J., Bruno M.J., Peppelenbosch M.P., Haagmans B.L., Pan Q., et al. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res. 2022;32:322–324. doi: 10.1038/s41422-022-00618-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-022-00618-w</ArticleId><ArticleId IdType="pmc">PMC8771185</ArticleId><ArticleId IdType="pubmed">35058606</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez J.-C., Moine P., Etting I., Annane D., Larabi I.A. Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a COVID-19 treated patient. Clin. Chem. Lab. Med. 2020;58:1461–1468. doi: 10.1515/cclm-2020-0612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2020-0612</ArticleId><ArticleId IdType="pubmed">32573468</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaidi A.K., Dehgani-Mobaraki P. The mechanisms of action of ivermectin against SARS-CoV-2—An extensive review. J. Antibiot. 2022;75:60–71. doi: 10.1038/s41429-021-00491-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41429-021-00491-6</ArticleId><ArticleId IdType="pmc">PMC8688140</ArticleId><ArticleId IdType="pubmed">34931048</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuyama S., Nao N., Shirato K., Kawase M., Saito S., Takayama I., Nagata N., Sekizuka T., Katoh H., Kato F., et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl. Acad. Sci. USA. 2020;117:7001–7003. doi: 10.1073/pnas.2002589117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2002589117</ArticleId><ArticleId IdType="pmc">PMC7132130</ArticleId><ArticleId IdType="pubmed">32165541</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiszniewski L., Jornot L., Dudez T., Pagano A., Rochat T., Lacroix J.S., Suter S., Chanson M. Long-term cultures of polarized airway epithelial cells from patients with cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 2006;34:39–48. doi: 10.1165/rcmb.2005-0161OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2005-0161OC</ArticleId><ArticleId IdType="pubmed">16179582</ArticleId></ArticleIdList></Reference><Reference><Citation>Spearman C. The method of ‘right and wrong cases’ (‘constant stimuli’) without gauss’s formulae. Br. J. Psychol. 1908;2:227–242. doi: 10.1111/j.2044-8295.1908.tb00176.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2044-8295.1908.tb00176.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Kärber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Naunyn Schmiedebergs Arch. Für Exp. Pathol. Und Pharmakol. 1931;162:480–483. doi: 10.1007/BF01863914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01863914</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan M.A. Determination of 50% endpoint titer using a simple formula. World J. Virol. 2016;5:85–86. doi: 10.5501/wjv.v5.i2.85.</Citation><ArticleIdList><ArticleId IdType="doi">10.5501/wjv.v5.i2.85</ArticleId><ArticleId IdType="pmc">PMC4861875</ArticleId><ArticleId IdType="pubmed">27175354</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber R.D., Harmer D.W., Coleman R.A., Clark B.J. GAPDH as a housekeeping gene: Analysis of GAPDH mRNA expression in a panel of 72 human tissues. Physiol. Genom. 2005;21:389–395. doi: 10.1152/physiolgenomics.00025.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiolgenomics.00025.2005</ArticleId><ArticleId IdType="pubmed">15769908</ArticleId></ArticleIdList></Reference><Reference><Citation>Günthard H.F., Saag M.S., Benson C.A., Del Rio C., Eron J.J., Gallant J.E., Hoy J.F., Mugavero M.J., Sax P.E., Thompson M.A., et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016;316:191–210. doi: 10.1001/jama.2016.8900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.8900</ArticleId><ArticleId IdType="pmc">PMC5012643</ArticleId><ArticleId IdType="pubmed">27404187</ArticleId></ArticleIdList></Reference><Reference><Citation>Naggie S., Muir A.J. Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs. Annu. Rev. Med. 2017;68:345–358. doi: 10.1146/annurev-med-052915-015720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-052915-015720</ArticleId><ArticleId IdType="pubmed">27686017</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan J.F.-W., Yuan S., Chu H., Sridhar S., Yuen K.-Y. COVID-19 drug discovery and treatment options. Nat. Rev. Microbiol. 2024;22:391–407. doi: 10.1038/s41579-024-01036-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-024-01036-y</ArticleId><ArticleId IdType="pubmed">38622352</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannalire R., Cerchia C., Beccari A.R., Di Leva F.S., Summa V. Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities. J. Med. Chem. 2022;65:2716–2746. doi: 10.1021/acs.jmedchem.0c01140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.0c01140</ArticleId><ArticleId IdType="pmc">PMC7688049</ArticleId><ArticleId IdType="pubmed">33186044</ArticleId></ArticleIdList></Reference><Reference><Citation>Martonik D., Parfieniuk-Kowerda A., Starosz A., Grubczak K., Moniuszko M., Flisiak R. Effect of antiviral and immunomodulatory treatment on a cytokine profile in patients with COVID-19. Front. Immunol. 2023;14:1222170. doi: 10.3389/fimmu.2023.1222170.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1222170</ArticleId><ArticleId IdType="pmc">PMC10358833</ArticleId><ArticleId IdType="pubmed">37483627</ArticleId></ArticleIdList></Reference><Reference><Citation>Moshawih S., Jarrar Q., Bahrin A.A., Lim A.F., Ming L., Goh H.P. Evaluating NSAIDs in SARS-CoV-2: Immunomodulatory mechanisms and future therapeutic strategies. Heliyon. 2024;10:e25734. doi: 10.1016/j.heliyon.2024.e25734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2024.e25734</ArticleId><ArticleId IdType="pmc">PMC10864964</ArticleId><ArticleId IdType="pubmed">38356603</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma G., Dhawan M., Saied A.A., Kaur G., Kumar R., Bin Emran T. Immunomodulatory approaches in managing lung inflammation in COVID-19: A double-edge sword. Immun. Inflamm. Dis. 2023;11:e1020. doi: 10.1002/iid3.1020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.1020</ArticleId><ArticleId IdType="pmc">PMC10521379</ArticleId><ArticleId IdType="pubmed">37773723</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenke K., Lewis M.C., Feldmann F., Bohrnsen E., Schwarz B., Okumura A., Bohler W.F., Callison J., Shaia C., Bosio C.M., et al. Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques. JCI Insight. 2023;8:e166485. doi: 10.1172/jci.insight.166485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.166485</ArticleId><ArticleId IdType="pmc">PMC9977490</ArticleId><ArticleId IdType="pubmed">36574296</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Sacramento C.Q., Jockusch S., Chaves O.A., Tao C., Fintelman-Rodrigues N., Chien M., Temerozo J.R., Li X., Kumar S., et al. Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture. Commun. Biol. 2022;5:154. doi: 10.1038/s42003-022-03101-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-022-03101-9</ArticleId><ArticleId IdType="pmc">PMC8863796</ArticleId><ArticleId IdType="pubmed">35194144</ArticleId></ArticleIdList></Reference><Reference><Citation>Peña-Silva R., Duffull S.B., Steer A.C., Jaramillo-Rincon S.X., Gwee A., Zhu X. Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19. Br. J. Clin. Pharmacol. 2021;87:1589–1590. doi: 10.1111/bcp.14476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.14476</ArticleId><ArticleId IdType="pmc">PMC7404744</ArticleId><ArticleId IdType="pubmed">32779815</ArticleId></ArticleIdList></Reference><Reference><Citation>Canga A.G., Prieto A.M.S., Liébana M.J.D., Martínez N.F., Vega M.S., Vieitez J.J.G. The pharmacokinetics and interactions of ivermectin in humans—A mini-review. AAPS J. 2008;10:42–46. doi: 10.1208/s12248-007-9000-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-007-9000-9</ArticleId><ArticleId IdType="pmc">PMC2751445</ArticleId><ArticleId IdType="pubmed">18446504</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>